Cefpodoxime

From Wikipedia, the free encyclopedia - View original article

Cefpodoxime
Cefpodoxime.svg
Systematic (IUPAC) name
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade namesGeneric (formerly Vantin)
AHFS/Drugs.commonograph
MedlinePlusa698024
Pregnancy cat.
Legal status
RoutesOral
Pharmacokinetic data
Bioavailability50%
Protein binding21% to 29%
MetabolismNegligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver
Half-life2 hours
ExcretionRenal, unchanged
Identifiers
CAS number82619-04-3 YesY
ATC codeJ01DD13
PubChemCID 6335986
DrugBankDB01416
ChemSpider4891496 YesY
UNII7R4F94TVGY N
KEGGD07650 YesY
ChEBICHEBI:3504 N
ChEMBLCHEMBL1672 YesY
Chemical data
FormulaC15H17N5O6S2 
Mol. mass427.458 g/mol
 N (what is this?)  (verify)
 
Jump to: navigation, search
Cefpodoxime
Cefpodoxime.svg
Systematic (IUPAC) name
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-acetyl]amino}-3-(methoxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
Trade namesGeneric (formerly Vantin)
AHFS/Drugs.commonograph
MedlinePlusa698024
Pregnancy cat.
Legal status
RoutesOral
Pharmacokinetic data
Bioavailability50%
Protein binding21% to 29%
MetabolismNegligible. Cefpodoxime proxetil is metabolized to cefpodoxime by the liver
Half-life2 hours
ExcretionRenal, unchanged
Identifiers
CAS number82619-04-3 YesY
ATC codeJ01DD13
PubChemCID 6335986
DrugBankDB01416
ChemSpider4891496 YesY
UNII7R4F94TVGY N
KEGGD07650 YesY
ChEBICHEBI:3504 N
ChEMBLCHEMBL1672 YesY
Chemical data
FormulaC15H17N5O6S2 
Mol. mass427.458 g/mol
 N (what is this?)  (verify)

Cefpodoxime is an oral, third-generation cephalosporin antibiotic. It is active against most Gram-positive and Gram-negative organisms. Notable exceptions include Pseudomonas aeruginosa, Enterococcus, and Bacteroides fragilis. Currently, it is only marketed as generic preparations in the USA, according the FDA Orange Book. It is commonly used to treat acute otitis media, pharyngitis, sinusitis, and gonorrhea. It also finds use as oral continuation therapy when intravenous cephalosporins (such as ceftriaxone) are no longer necessary for continued treatment.

Pfizer, the parent company of Pharmacia & Upjohn, markets cefpodoxime proxetil under the trade name C-Doxim for veterinary use. The dose range in dogs is 5–10 mg/kg body weight, administered orally, once a day.

Finecure, India markets the products under trade name Cefpo.[1]

Cefpodoxime inhibits cell wall synthesis by inhibiting the final transpeptidation step of peptidoglycan synthesis in cell walls. It has well established pharmacokinetic profile with absorption of 50%. It is indicated in community acquired pneumonia, uncomplicated skin and skin structure infections, and uncomplicated urinary tract infections.

Structural formula of cefpodoxime proxetil

Spectrum of bacterial susceptibility and resistance[edit]

Cefpodoxime has been used to fight pathogenic bacteria responsible for causing gonorrhoea, tonsillitis, pneumonia, and bronchitis. Representative pathogenic genera include Streptococcus, Haemophilus, and Neisseria. The following represents MIC susceptibility data for a few medically significant microorganisms.

[2]

References[edit]

  1. ^ "Anti Biotics and Anti Bacterial". Finecurepharmaceuticalsltd. Retrieved 2012-03-27. 
  2. ^ http://www.toku-e.com/Assets/MIC/Cefpodoxime%20Free%20acid.pdf

External links[edit]